Research programme: direct-acting antivirals - Antiva Biosciences

Drug Profile

Research programme: direct-acting antivirals - Antiva Biosciences

Alternative Names: ABI-1968; HTI-1968

Latest Information Update: 26 Sep 2016

Price : $50

At a glance

  • Originator Hera Therapeutics
  • Developer Antiva Biosciences
  • Class Small molecules
  • Mechanism of Action Apoptosis stimulants; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Anal intraepithelial neoplasia; Cervical intraepithelial neoplasia; Vulvar intraepithelial neoplasia
  • Research Herpesvirus infections; HIV infections; Human papillomavirus infections

Most Recent Events

  • 26 Sep 2016 Preclinical trials in Vulvar intraepithelial neoplasia in USA (Topical) (Antiva Biosciences pipeline, September 2016)
  • 26 Sep 2016 Antiva Biosciences plans a phase Ib trial for Vulvar intraepithelial neoplasia in USA (Antiva Biosciences pipeline, September 2016)
  • 31 Aug 2016 Preclinical trials in Anal intraepithelial neoplasia in USA (Topical) prior to August 2016 (Antiva Biosciences pipeline, August 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top